AU Patent

AU2023228095A1 — Process of making a crystalline edg-2 receptor antagonist

Assigned to Horizon Therapeutics Ireland DAC · Expires 2024-08-15 · 2y expired

What this patent protects

Described herein are methods of making crystalline Form 1 of 2-(4-methoxy-3-(3- methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid.

USPTO Abstract

Described herein are methods of making crystalline Form 1 of 2-(4-methoxy-3-(3- methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023228095A1
Jurisdiction
AU
Classification
—
Expires
2024-08-15
Drug substance claim
No
Drug product claim
No
Assignee
Horizon Therapeutics Ireland DAC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.